A recent analysis in Daily Maverick examines the complex landscape surrounding GLP-1 medications, originally developed for diabetes but now prominent for chronic obesity. The report highlights that while these drugs offer transformative health benefits, their adoption is complicated by persistent social stigma, high costs, and the short-term thinking of medical insurers. Steven Boykey Sidley explores the tension between medical efficacy and the societal structures limiting accessibility.
The origins of GLP-1s trace back to 1992, when endocrinologist John Eng studied the Gila monster. Eng identified a compound in the lizard’s saliva similar to the human hormone glucagon-like peptide-1. This discovery led to FDA approval of synthetic versions for type 2 diabetes in 2005 and for chronic obesity in 2014. Public attention grew in 2021 with the approval of Wegovy. Despite success, these treatments collided with moral beliefs about body weight as a measure of discipline.
Social prejudice remains significant. Research in the International Journal of Obesity in 2026 found that people using these drugs were judged more negatively than those using diet and exercise. The study noted additional stigma if users regain weight after stopping. A UK survey by Simple Online Pharmacy found 66% of patients conceal treatment, while 38% reported being judged. Although openness has increased, embarrassment persists among users.
The question of stopping medication involves contradictory truths. GLP-1s are not physically addictive and may dampen other addictive behaviors. However, studies show users typically regain around two-thirds of weight loss within a year of stopping. The report emphasizes these are ongoing treatments for a chronic condition rather than a cure. Side effects are described as mostly digestive and temporary, with no evidence of long-term harm outweighing benefits.
Financial barriers and insurance policies present major hurdles. Treatments in the US can cost upwards of $150 per month, a price point that remains high globally. Dr. Zeke Emanuel explained on a Freakonomics podcast that insurers resist coverage because they bear treatment costs while future insurers reap long-term health savings. This structure disincentivizes long-term investment in preventive care, leaving patients to navigate a system that penalizes them for seeking effective treatment.